Jade Biosciences, Inc. (JBIO) News
Follow Jade Biosciences, Inc. (JBIO) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 10 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Jade Bios reports potent preclinical JADE301 data, 30-day NHP half-life and Phase 1 start planned
Jade Bios announced preclinical data showing JADE301 potently neutralizes IFN-ß and supports infrequent subcutaneous dosing.Key Highlights:Original SEC Filing: Jade Biosciences, Inc. [ JBIO ] - 8-K - Sep. 30, 2026This is
REGULATION | Sep 30, 2026, 11:23 AM UTC
L
Jade Biosciences, Inc. (JBIO) Reports Preclinical Data on Anti-IFN-β Antibody JADE301
Jade Biosciences reported preclinical data for JADE301, a half-life-extended anti-IFN-β mAb for dermatomyositis, and expects to start a placebo-controlled, single ascending-dose Phase 1 study in Q4 2026 with interim data
NEWS | Sep 30, 2026, 11:08 AM UTC
L
Jade Biosciences Announces Preclinical Data Characterizing Jade301, A Potentially Best-In-Class, Half-Life-Extended Anti-Ifn-Β Monoclonal Antibody In Development For Dermatomyositis, At Eadv 2026
Jade Biosciences, Inc. NASDAQ:JBIO
NEWS | Sep 30, 2026, 11:02 AM UTC
L
JBIO highlights JADE101 progress in IgA nephropathy pipeline expansion
Jade Bioscience says JADE101 shows best-in-class potential in IgA nephropathy and rapid clinical progress, alongside three advanced autoimmune therapeutics. The company cites strong financials and strategic trial designs
EQUITY | Sep 09, 2026, 02:54 PM UTC
L
JBIO: JADE101 shows best-in-class promise for IgA nephropathy, with pivotal trials and broad expansion ahead
The team presented a robust pipeline targeting autoimmune diseases, highlighting JADE101's best-in-class potential in IgA nephropathy with strong phase I data and a rapid path to pivotal trials. Market opportunity is sig
EQUITY | Sep 09, 2026, 02:27 PM UTC
L
JBIO: JADE101’s quarterly dosing and potent IgA reduction position it as a leading therapy in IgAN
The company is advancing three main assets targeting autoimmune diseases, with JADE101 showing strong phase I results in IgA nephropathy and moving rapidly into phase II and III. Differentiation is based on potency, dosi
EQUITY | Sep 08, 2026, 09:53 PM UTC
L
JBIO advances JADE101 in IgA nephropathy toward phase II and III
JBIO is progressing three autoimmune-disease assets. JADE101 posted strong phase I results in IgA nephropathy and is moving into phase II and III, supported by differentiation on potency, dosing convenience and safety.
EQUITY | Sep 08, 2026, 08:55 PM UTC
L
Jade Biosciences to participate in upcoming conferences
Jade Biosciences, a clinical-stage biotech focused on autoimmune disease therapies, announced its participation in upcoming conferences in San Francisco and Vancouver.
EQUITY | Sep 01, 2026, 11:07 AM UTC
L
JBIO - Jade Biosciences to Participate in Upcoming Conferences
JBIO - Jade Biosciences to Participate in Upcoming Conferences
EQUITY | Sep 01, 2026, 11:00 AM UTC
L
Jade Biosciences Enters Exclusive Worldwide License Agreement With Paragon Therapeutics; To Pay Up To $22M In Milestone Payments To Paragon;
SEC Filing
REGULATION | Jul 01, 2026, 09:20 PM UTC